Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptic-ulcer disease.

Francis K L Chan1, W K Leung

  • 1Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China. fklchan@cuhk.edu.hk

Lancet (London, England)
|October 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fecal Microbiota Transplantation for Symptom Improvement in Patients With Irritable Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Gastroenterology·2026
Same author

Risk of Complicated Upper Gastrointestinal Bleeding With Direct Oral Anticoagulants: An Asian Population-Based Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Microbiome biomarkers in autism spectrum disorder: Toward prediction, diagnosis, and prognosis.

Cell reports. Medicine·2026
Same author

Quantifying artificial sweeteners and emulsifiers in Crohn's disease and its relationship with disease activity: the ENIGMA study - a novel and targeted approach.

Gut·2026
Same author

Gastrointestinal Bleeding and Cardiovascular Risk: From Association to Actionable Evidence.

Gastroenterology·2026
Same author

Future-proofing medicine for a world of volatility, uncertainty, complexity, and ambiguity.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

The discovery of Helicobacter pylori impacts peptic ulcer disease management. While uncomplicated ulcers decline, NSAID-related complications rise, necessitating evolving treatment strategies for bacterial and drug-induced ulcers.

Area of Science:

  • Gastroenterology
  • Microbiology

Background:

  • Peptic ulcer disease is influenced by bacterial, host, and environmental factors.
  • Helicobacter pylori discovery revolutionized understanding and treatment of peptic ulcers.
  • Uncomplicated peptic ulcer prevalence is decreasing, but NSAID-associated complications are increasing.

Purpose of the Study:

  • To review the evolving landscape of peptic ulcer disease.
  • To discuss the interplay between Helicobacter pylori and non-steroidal anti-inflammatory drugs (NSAIDs).
  • To examine the impact of new therapeutic strategies on gastroduodenal ulceration.

Main Methods:

  • Literature review of peptic ulcer disease management.
  • Analysis of trends in ulcer prevalence and complications.
  • Evaluation of therapeutic advances including NSAIDs, antiulcer agents, and COX-2 inhibitors.

Related Experiment Videos

Main Results:

  • NSAID use is linked to rising hospital admissions for ulcer complications.
  • Prescribing NSAIDs with antiulcer agents or COX-2 inhibitors may reduce ulceration.
  • The declining rate of H. pylori infection shifts the proportion of ulcers unrelated to H. pylori and NSAIDs.

Conclusions:

  • Therapeutic advances in managing NSAID-induced ulcers show promise but require clinical validation.
  • The changing etiology of peptic ulcers, with fewer H. pylori-related cases, necessitates adaptive management strategies.
  • Understanding the complex interaction between H. pylori and NSAIDs remains crucial for effective peptic ulcer disease treatment.